This study aims to evaluate the effectand safety of empasiprubart compared with intravenous immunoglobulin (IVIg) treatment in adults with multifocal motor neuropathy (MMN). This study will also check how empasiprubart affects the body, how it is absorbed and removed from the body, and how the immune system reacts to empasiprubart.

The aim of this study is to measure the efficacy (how well it works) and safety of efgartigimod compared with placebo (inactive substance) in participants with ocular myasthenia gravis (oMG). The study will also measure the long-term efficacy, safety, and tolerability of efgartigimod.

In this study, we are trying to find out how safe and helpful a new drug is when it is put directly into the brain during surgery. This drug is used to help with the movement problems caused by Parkinson's disease.

Do you have problems with your thinking or memory? Or a parent or sibling with dementia? If so, we'd like you to join this registry about the brain and Alzheimer's disease. In return for providing us with a little bit of your health history and background, we will connect you with researchers doing studies you can join, without obligation. Many studies pay a stipend and some offer a possible treatment.

The purpose of this study is to identify and genomically-characterize individuals with genetically unexplained neurodevelopmental disorders, such as epilepsy. The overarching goal is to provide patients with improved information about the underlying genetic basis of their disorder and illuminate novel genetically-defined treatment approaches in the future.

Do you have probable Dementia with Lewy Bodies (DLB), Mild Cognitive Impairment with "high likelihood" DLB, or Parkinson's Disease Dementia (PDD)? You may be able to participate in an observational study to track your disease progression and promote future research.

The ASPIRE trial aims to study anticoagulant medications in patients who have had an intracerebral hemorrhage (bleeding in the brain) who also have atrial fibrillation (irregular heartbeats). Participants who agree to study participation will receive either Aspirin or Apixaban and followed for 12-36 months to see if they have any other strokes, and follow their general recovery after stroke.

This study will gather information about patients who are taking new medicines for Alzheimer's disease. We'll keep an eye on how these patients are doing in the long run, tracking things like how they're responding to treatment, what their overall health outcomes are like, and how safe these new treatments really are when used in the real world. The goal of this study is to get a better understanding of how these therapies actually work for a diverse group of people, not just the people who usually participate in clinical trials.

This clinical trial aims to understand how well ALXN-C5IT works over a long time. We want to see if it can prevent relapses and help with disability, walking, and vision. We also want to know how patients feel about their health while using ALXN-C5IT.